The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Autolus Therapeutics plc ADR (NASDAQ: AUTL) closed at $2.28 in the last session, down -1.30% from day before closing price of $2.31. In other words, the price has decreased by -$1.30 from its previous closing price. On the day, 2.32 million shares were traded. AUTL stock price reached its highest trading level at $2.345 during the session, while it also had its lowest trading level at $2.235.
Ratios:
We take a closer look at AUTL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.99 and its Current Ratio is at 9.21. In the meantime, Its Debt-to-Equity ratio is 0.84 whereas as Long-Term Debt/Eq ratio is at 0.83.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on November 18, 2024, Upgraded its rating to Buy and sets its target price to $7.60 from $7 previously.
On November 15, 2024, Redburn Atlantic Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $13.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $10.Deutsche Bank initiated its Buy rating on November 09, 2023, with a $10 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 16 ’24 when Martin Pule bought 698,741 shares for $4.23 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUTL now has a Market Capitalization of 606794624 and an Enterprise Value of 401372416. For the stock, the TTM Price-to-Sale (P/S) ratio is 67.35 while its Price-to-Book (P/B) ratio in mrq is 1.64. Its current Enterprise Value per Revenue stands at 44.542 whereas that against EBITDA is -1.549.
Stock Price History:
The Beta on a monthly basis for AUTL is 1.81, which has changed by -0.3254438 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, AUTL has reached a high of $5.00, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is 31.93%, while the 200-Day Moving Average is calculated to be -7.56%.
Shares Statistics:
According to the various share statistics, AUTL traded on average about 2.32M shares per day over the past 3-months and 1996080 shares per day over the past 10 days. A total of 266.14M shares are outstanding, with a floating share count of 240.33M. Insiders hold about 9.70% of the company’s shares, while institutions hold 54.13% stake in the company. Shares short for AUTL as of 1749772800 were 12714466 with a Short Ratio of 5.47, compared to 1747267200 on 10586405. Therefore, it implies a Short% of Shares Outstanding of 12714466 and a Short% of Float of 6.29.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Currently, 5.0 analysts are dedicated to thoroughly evaluating and rating the performance of Autolus Therapeutics plc ADR (AUTL) in the stock market.The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.18 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.52 and -$1.25 for the fiscal current year, implying an average EPS of -$0.9. EPS for the following year is -$0.79, with 7.0 analysts recommending between -$0.35 and -$1.19.
Revenue Estimates
For the next quarter, 8 analysts are estimating revenue of $16.51M. There is a high estimate of $23.39M for the next quarter, whereas the lowest estimate is $9.85M.
A total of 9 analysts have provided revenue estimates for AUTL’s current fiscal year. The highest revenue estimate was $77.96M, while the lowest revenue estimate was $38.54M, resulting in an average revenue estimate of $56.97M. In the same quarter a year ago, actual revenue was $10.12MBased on 9 analysts’ estimates, the company’s revenue will be $130.69M in the next fiscal year. The high estimate is $265.64M and the low estimate is $65.15M.
